{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Olanzapine&page=2",
    "query": {
      "intervention": "Olanzapine",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Olanzapine&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-29T13:00:52.891Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00088478",
      "title": "Comparison of Intramuscular Olanzapine Depot With Placebo in the Treatment of Patients With Schizophrenia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "Intramuscular Olanzapine Depot",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 402,
      "start_date": "2004-06",
      "completion_date": "2005-04",
      "has_results": false,
      "last_update_posted_date": "2007-06-12",
      "last_synced_at": "2026-09-29T13:00:52.891Z",
      "location_count": 34,
      "location_summary": "National City, California • Orange, California • Rosemead, California + 31 more",
      "locations": [
        {
          "city": "National City",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Rosemead",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Santa Ana",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00088478"
    },
    {
      "nct_id": "NCT03899506",
      "title": "Olanzapine Versus Midazolam for Agitation",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Agitation,Psychomotor"
      ],
      "interventions": [
        {
          "name": "Olanzapine",
          "type": "DRUG"
        },
        {
          "name": "Midazolam",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hennepin Healthcare Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 206,
      "start_date": "2018-06-18",
      "completion_date": "2018-07-16",
      "has_results": false,
      "last_update_posted_date": "2019-05-13",
      "last_synced_at": "2026-09-29T13:00:52.891Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03899506"
    },
    {
      "nct_id": "NCT00205738",
      "title": "Janssen - Glucose Regulation/Risp/Olanz",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Schizophrenia",
        "Type 2 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Risperidone, Olanzapine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 120,
      "start_date": "2000-07",
      "completion_date": "2006-10",
      "has_results": false,
      "last_update_posted_date": "2014-03-13",
      "last_synced_at": "2026-09-29T13:00:52.891Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00205738"
    },
    {
      "nct_id": "NCT03857581",
      "title": "Clozapine Versus Olanzapine as Treatment for Comorbid Psychotic Disorder and Substance Use Disorder",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Psychosis",
        "Substance Use Disorders"
      ],
      "interventions": [
        {
          "name": "Clozapine",
          "type": "DRUG"
        },
        {
          "name": "Olanzapine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Augusta University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 100,
      "start_date": "2020-07",
      "completion_date": "2021-07",
      "has_results": false,
      "last_update_posted_date": "2020-03-23",
      "last_synced_at": "2026-09-29T13:00:52.891Z",
      "location_count": 1,
      "location_summary": "Evans, Georgia",
      "locations": [
        {
          "city": "Evans",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03857581"
    },
    {
      "nct_id": "NCT05179772",
      "title": "Olanzapine in OUD Patients",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Opioid Use Disorder"
      ],
      "interventions": [
        {
          "name": "Olanzapine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Pennsylvania",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 0,
      "start_date": "2022-07-28",
      "completion_date": "2023-01-30",
      "has_results": false,
      "last_update_posted_date": "2023-02-01",
      "last_synced_at": "2026-09-29T13:00:52.891Z",
      "location_count": 2,
      "location_summary": "Philadelphia, Pennsylvania • Richmond, Virginia",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Richmond",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05179772"
    },
    {
      "nct_id": "NCT00845507",
      "title": "Exenatide for the Treatment of Weight Gain Associated With Olanzapine in Obese Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Weight Gain"
      ],
      "interventions": [
        {
          "name": "Exenatide",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Cincinnati",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 54,
      "start_date": "2008-12",
      "completion_date": "2015-07",
      "has_results": true,
      "last_update_posted_date": "2018-04-20",
      "last_synced_at": "2026-09-29T13:00:52.891Z",
      "location_count": 1,
      "location_summary": "Cincinnati, Ohio",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00845507"
    },
    {
      "nct_id": "NCT00845026",
      "title": "A Safety Study Comparing LY2140023 to Atypical Antipsychotic Standard Treatment in Schizophrenic Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "LY2140023",
          "type": "DRUG"
        },
        {
          "name": "aripiprazole",
          "type": "DRUG"
        },
        {
          "name": "olanzapine",
          "type": "DRUG"
        },
        {
          "name": "risperidone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Denovo Biopharma LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 261,
      "start_date": "2009-03",
      "completion_date": "2010-12",
      "has_results": true,
      "last_update_posted_date": "2022-11-08",
      "last_synced_at": "2026-09-29T13:00:52.891Z",
      "location_count": 11,
      "location_summary": "Escondido, California • Garden Grove, California • Washington D.C., District of Columbia + 8 more",
      "locations": [
        {
          "city": "Escondido",
          "state": "California"
        },
        {
          "city": "Garden Grove",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Hoffman Estates",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00845026"
    },
    {
      "nct_id": "NCT02282085",
      "title": "Treatment Study Comparing Aripiprazole Once Monthly With Standard of Care Medication in Outpatients With Schizophrenia",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "Aripiprazole Once-Monthly",
          "type": "DRUG"
        },
        {
          "name": "Oral Antipsychotic (i.e. aripiprazole, risperidone, lurasidone, quetiapine, olanzapine, ziprasidone, etc)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Matt Byerly",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 200,
      "start_date": "2014-12",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2015-06-08",
      "last_synced_at": "2026-09-29T13:00:52.891Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02282085"
    },
    {
      "nct_id": "NCT02694328",
      "title": "A Study of ALKS 3831 in Adults With Schizophrenia (The ENLIGHTEN-2 Study)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "ALKS 3831",
          "type": "DRUG"
        },
        {
          "name": "Olanzapine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alkermes, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 561,
      "start_date": "2016-03-02",
      "completion_date": "2018-11-07",
      "has_results": true,
      "last_update_posted_date": "2020-02-10",
      "last_synced_at": "2026-09-29T13:00:52.891Z",
      "location_count": 52,
      "location_summary": "Little Rock, Arkansas • Springdale, Arkansas • Anaheim, California + 46 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Springdale",
          "state": "Arkansas"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Cerritos",
          "state": "California"
        },
        {
          "city": "Culver City",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02694328"
    },
    {
      "nct_id": "NCT05857566",
      "title": "Effect of RDX-002 on Postprandial Triglycerides in Subjects Treated With Olanzapine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Drug-induced Weight Gain"
      ],
      "interventions": [
        {
          "name": "RDX-002",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Response Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 24,
      "start_date": "2023-05-16",
      "completion_date": "2023-09-13",
      "has_results": false,
      "last_update_posted_date": "2023-11-18",
      "last_synced_at": "2026-09-29T13:00:52.891Z",
      "location_count": 1,
      "location_summary": "Saint Paul, Minnesota",
      "locations": [
        {
          "city": "Saint Paul",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05857566"
    }
  ]
}